SCHEMBL1764091

SCHEMBL1764091

COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.79
CYP3A4 P08684 3/20 0.79
MAPT P10636 2/20 0.79
MAPK1 P28482 2/20 0.79
MEN1 O00255 2/20 0.79
ABCB1 P08183 2/20 0.79
KMT2A Q03164 2/20 0.79
ABCG2 Q9UNQ0 2/20 0.79
KDM4E B2RXH2 1/20 0.79
HPGD P15428 1/20 0.79
HSD17B10 Q99714 1/20 0.79
CYP1A1 P04798 2/20 0.73
CYP1B1 Q16678 2/20 0.73
USP2 O75604 1/20 0.72
LMNA P02545 1/20 0.72
ELANE P08246 1/20 0.72
AURKA O14965 1/20 0.67
KDR P35968 1/20 0.67
FLT3 P36888 1/20 0.67
AURKB Q96GD4 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30082749 1.00 ALDH1A1 (0.79) ALDH1A1CYP3A4MAPTMAPK1MEN1
SCHEMBL1764085 0.93 ALDH1A1 (0.84) ALDH1A1CYP3A4MAPTMAPK1MEN1
SCHEMBL30082747 0.90 ALDH1A1 (0.79) ALDH1A1CYP3A4MAPTMAPK1MEN1
SCHEMBL678646 0.90 ALDH1A1 (0.79) ALDH1A1CYP3A4MAPTMAPK1MEN1
SCHEMBL30445844 0.90 BCL2 (0.79) ALDH1A1CYP3A4MAPTMAPK1MEN1
SCHEMBL1764426 0.90 BCL2 (0.79) ALDH1A1CYP3A4MAPTMAPK1MEN1
SCHEMBL16894632 0.89 ACHE (0.76) ALDH1A1CYP3A4MAPTMAPK1CYP1A1
Nobiletin SCHEMBL22092292 0.88 ALDH1A1 (1.00) ALDH1A1CYP3A4MAPTMAPK1MEN1
Nobiletin SCHEMBL29374681 0.88 ALDH1A1 (1.00) ALDH1A1CYP3A4MAPTMAPK1MEN1
Nobiletin SCHEMBL30049905 0.88 ALDH1A1 (1.00) ALDH1A1CYP3A4MAPTMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140039044-A1 Hydroxylated Polymethoxyflavone Compositions WLLGEN, INC. (US) 2014-02-06 US claimed
EP-2010194-A2 HYDROXYLATED POLYMETHOXYFLAVONE COMPOSITIONS Rutgers, The State University of New Jersey (US) 2009-01-07 EP claimed
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions WELLGEN, INC. 2007-11-29 US claimed
WO-2007109071-A2 HYDROXYLATED POLYMETHOXYFLAVONE COMPOSITIONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-09-27 WO claimed
US-20240114939-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE FIRMENICH SA (CH) 2024-04-11 US disclosed
EP-4258899-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE Firmenich SA (CH) 2023-10-18 EP disclosed
WO-2022189155-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE FIRMENICH SA (CH) 2022-09-15 WO disclosed
US-20140039044-A1 Hydroxylated Polymethoxyflavone Compositions WLLGEN, INC. (US) 2014-02-06 US disclosed
US-20110123653-A1 COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2011-05-26 US disclosed
EP-1883300-A2 COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY Rutgers, The State University of New Jersey (US) 2008-02-06 EP disclosed
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions WELLGEN, INC. 2007-11-29 US disclosed
US-20070088078-A1 Methods for managing adipocyte fat accumulation WELLGEN, INC. 2007-04-19 US disclosed
US-20070042972-A1 Compositions and methods for optimizing exercise recovery RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2007-02-22 US disclosed
WO-2006127996-A2 COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042972-A1 Compositions and methods for optimizing exercise recovery GYS1, PYGM, PRDX5 ALDH1A1 3163/4885CYP3A4 144/4885MAPT 4515/4885
US-20070088078-A1 Methods for managing adipocyte fat accumulation FABP4, PLIN5, PLIN3 ALDH1A1 1272/4885CYP3A4 1574/4885MAPT 3872/4885
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions PLIN5, FANCF, COXFA4 ALDH1A1 1794/4885CYP3A4 390/4885MAPT 4329/4885
US-20110123653-A1 COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY GYS1, PYGM, PRDX5 ALDH1A1 3163/4885CYP3A4 144/4885MAPT 4515/4885
US-20140039044-A1 Hydroxylated Polymethoxyflavone Compositions PLIN5, FANCF, COXFA4 ALDH1A1 1794/4885CYP3A4 390/4885MAPT 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.